REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
← catalyst calendarNCT07410117 · readout in 1,253 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
1,120estimated
Sites
13
Countries
Georgia, Japan, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-09 | actual | When the study began enrolling |
| Primary completion | 2030-01-23 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-05-06 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cancer-Associated Thrombosis (CAT)
Interventions
- Drug: REGN7508 — also filed as cenvacibart
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFTime-to-first event of centrally adjudicated VTE (DVT, PE) or ATE, or thromboembolism- or ATE-related death
measured Through 6 months
Time-to-first event of centrally adjudicated International Society of Thrombosis and Hemostasis (ISTH) major bleeding or Clinically Relevant Non-Major (CRNM) bleeding
measured Through 6 months
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed